LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs for cardiovascular, metabolic, and neurological disorders. The company's primary marketed product is Sotagliflozin, an orally-delivered therapeutic that reduces the risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and associated cardiovascular risk factors. The company has established strategic partnerships with Viatris Inc. and Bristol-Myers Squibb Company to support commercialization and development efforts.

Lexicon's pipeline includes multiple drug candidates in clinical development. Sotagliflozin is being evaluated in Phase 3 trials for hypertrophic cardiomyopathy and type 1 diabetes. LX9211, which completed Phase 2 testing, targets neuropathic pain treatment. LX9851 is in development for obesity and associated cardiometabolic disorders, as well as weight management applications.

The company operates with approximately 103 full-time employees and maintains headquarters in The Woodlands, Texas. As a Nasdaq-listed entity incorporated in Delaware, Lexicon operates with a market capitalization of $0.6 billion. The company's revenue model centers on product commercialization and potential milestone payments from partnership agreements.